Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 17344334.
- Also identified by PMC identifier 1994395.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To compare the effectiveness of statins of different treatment intensity used to treat elderly patients with acute coronary syndrome (ACS) in typical care settings. Retrospective cohort study using linked hospital and pharmacy claims data. Statewide pharmacy benefits programmes in Pennsylvania and New Jersey. 18,311 Medicare patients discharged alive after ACS who received a prescription for a statin within 90 days of hospital discharge. Using multivariable and propensity-matched Cox proportional hazards regression models, patients who were prescribed high-intensity and moderate-intensity statins were compared based on the drug-dose combination that they initially received. Individual drug-dose combinations were also compared. Our primary outcome was the composite of all-cause death or recurrent ACS. Patients who received moderate-intensity statins were as likely to experience a primary outcome as patients treated with high-intensity statins (adjusted HR 1.02, 95% CI 0.96 to 1.08). Propensity matching did not change the results. Individually, all moderate-intensity statins were as effective as high-intensity atorvastatin with the exception of lovastatin (adjusted HR 1.22, 95% CI 1.09 to 1.36). Similarly, all high-intensity statins seem as effective as high-intensity atorvastatin but the CIs surrounding these estimates were wide. This analysis of elderly patients with ACS treated in typical care settings does not demonstrate the superiority of high-intensity over moderate-intensity statin treatment or significant differences among individual statins.
Medical subject headings
- Coronary Disease
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hypolipidemic Agents